← Back to list
Biofeedback as a Treatment of Urinary Incontinence in Adults
Effective date
Not stated in the notice
Identified
Jun 20, 2026
Summary
Biofeedback is considered investigational as a treatment of urinary incontinence in adults. The policy describes biofeedback in conjunction with pelvic floor muscle training as a possible treatment modality for stress, urge, mixed, and overflow urinary incontinence. The leva Pelvic Health system received FDA approval in 2022 for fecal incontinence, urinary incontinence, and strengthening of the pelvic floor muscles.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.
What to do
Action · 3 steps
01Claims for biofeedback as a treatment of urinary incontinence in adults are investigational under this policy.
02Federal Employee Program (FEP) may dictate that FDA-approved devices may not be considered investigational and may be assessed only on the basis of their medical necessity.
03Biofeedback training codes 90912 and 90913 and the EMG biofeedback device code E0746 are listed as investigational codes in this policy.
Codes mentioned
9087590876909019091290913E0746
Original notice
Biofeedback as a Treatment of Urinary Incontinence in Adults
bcbsms.com · Always check the source before changing claims.